Verona Pharma plc

Jurisdiction

United Kingdom

LEI

213800EVI6O6J3TIAL06

ISIN

US9250501064

(VRNA)

Sectors

Scores

InsiderPie Expert Score: 49 / 100
Even with peer group:: 49 / 100
Fair value (Benjamin Graham formula): N/A
Financial strength (Piotroski F-Value): 5 / 9
Fundamental strength relative to industry (Mohanram G-Value): 5 / 7

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Read full profile

Fundamentals

Net revenue: €189.08M
Gross margin: 95.2%
EBIT: -€47.78M
EBIT margin: -25.3%
Net income: -€69.25M
Net margin: -36.6%

Statement period: July 1, 2024 - June 30, 2025 (published August 6, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€653.47M +245.6%	€246.14M -455.5%
2027	€1.07B +63.6%	€557.48M +126.5%
2028	€1.51B +41.4%	€692.43M +24.2%

Dividends

No dividend payouts

Analyst ratings

No analyst ratings available

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
ACKERMANN CHRISTINA	N/A	August 1, 2025	-1.8K	$13.14	-$23.76K
Austwick Michael	N/A	August 1, 2025	-11K	$13.14	-$148.32K
Brady James Aloysius	N/A	August 1, 2025	-824	$13.14	-$10.83K
Cunningham Kenneth	N/A	August 1, 2025	-11K	$13.14	-$142.02K
Deschamps Lisa	N/A	August 1, 2025	-9.5K	$13.14	-$124.36K